← Back to guidelines
Cardiology6 papers

Mucosa-associated lymphoma

Last edited: 4/22/2026

Overview

Mucosa-associated lymphoid tissue (MALT) lymphomas, particularly those associated with HIV, often exhibit plasmablastic features and aggressive behavior, frequently involving extramedullary and extranodal sites such as the oral cavity, bone, soft tissue, and gastrointestinal tract 1.

Diagnosis

  • Morphological Features: Marked plasmacytic differentiation, homogeneous morphology, CD45+, CD20-, PAX-5-, CD138+ 1.
  • Immunophenotyping: Positive for Epstein-Barr virus-encoded RNA (EBER), negative for EBV late membrane proteins (LMP) 1.
  • Viral Markers: Detection of Human herpes virus 8 (HHV8) DNA via nested PCR, though absence of HHV8 latent nuclear antigen (LNA) noted 1.
  • Imaging: CT scans crucial for identifying disseminated tumor masses and guiding diagnosis, especially in suspected cases 2.
  • HIV Screening: Essential in patients with aggressive lymphomas, particularly in pediatric populations 2.
  • Management

  • Treatment: Specific drug classes and doses not detailed in provided abstracts; aggressive management typically required 1.
  • Supportive Care: Focus on symptom management and supportive therapies given the aggressive nature and poor prognosis 1.
  • Special Populations

  • Pediatrics: HIV-associated lymphomas can present with atypical neurological symptoms in children, necessitating thorough diagnostic workup including CT scans 2.
  • Comorbidities: HIV infection significantly impacts prognosis, with all observed patients in the study having poor outcomes 1.
  • Key Recommendations

  • Screen HIV-positive patients with aggressive lymphomas for EBV and HHV8 markers to guide diagnosis and prognosis (Evidence: Moderate 1).
  • Include CT imaging in the diagnostic workup of suspected lymphoma, especially in pediatric cases with atypical presentations (Evidence: Weak 2).
  • Aggressive management strategies are warranted given the poor outcomes observed in HIV-associated lymphomas; specific therapeutic protocols should be tailored to individual patient factors (Evidence: Expert opinion 1).
  • References

    1 Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. The American journal of surgical pathology 2005. link 2 Ogunseyinde AO, Familusi JB. HIV-assocated lymphoma: a case report. African journal of medicine and medical sciences 2002. link

    Original source

    1. [1]
      Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm.Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL The American journal of surgical pathology (2005)
    2. [2]
      HIV-assocated lymphoma: a case report.Ogunseyinde AO, Familusi JB African journal of medicine and medical sciences (2002)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG